Skip to main content
Clinical Trials/EUCTR2018-000059-42-FR
EUCTR2018-000059-42-FR
Active, not recruiting
Phase 1

Comparison of short infusion versus prolonged infusion of ceftolozane-tazobactam among patients with ventilator associated-pneumonia to Pseudomonas aeruginosa in intensive care units - CEFTOREA

CHU DE TOULOUSE0 sites60 target enrollmentApril 9, 2018
DrugsZERBAXA

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
CHU DE TOULOUSE
Enrollment
60
Status
Active, not recruiting
Last Updated
7 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 9, 2018
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
CHU DE TOULOUSE

Eligibility Criteria

Inclusion Criteria

  • Age \= 18 years
  • patients with ventilator associated\-pneumonia to Pseudomonas aeruginosa
  • patients hospitalized in intensive care units
  • Pseudomonas aeruginosa susceptible to ceftolozane\-tazobactam
  • SAPS II (Simplified Acute. Physiological Score II) \> 20
  • Expected duration of survival \> 7 days
  • Informed consent of the patient or, failing that, the patient’s close or trustworthy person
  • Affiliated to a social security scheme or equivalent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:

Exclusion Criteria

  • history of allergy to one of the two molecules
  • history of allergy to betalactamines
  • Strain Isolated resistant to Ceftolozane\-Tazobactam combination
  • Renal insufficiency with a glomerular filtration rate evaluated by CKD\-EPI \< 50 ml/min
  • Patient on dialysis or under continuous hemodiafiltration
  • Pregnant or nursing women
  • Patient benefiting from a system of legal protection for adults

Outcomes

Primary Outcomes

Not specified

Similar Trials